# A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

> **NCT02848001** · PHASE1 · TERMINATED · sponsor: **Celgene** · enrollment: 101 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** CC-90009

## Key facts

- **NCT ID:** NCT02848001
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-11-14
- **Primary completion:** 2023-04-11
- **Final completion:** 2024-04-11
- **Target enrollment:** 101 (ACTUAL)
- **Why stopped:** Trial terminated because of lack of efficacy in the short term acute phase.
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02848001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02848001, "A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02848001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*